Full Breakdown
Groundbreaking HIV Prevention Injection to Be Available at $40 Annually by 2027
9/27/2025, 12:55:59 AM
Introduction of Lenacapavir
A significant advancement in HIV prevention is set to occur with the introduction of lenacapavir, a twice-yearly injectable drug that will be available at a cost of $40 per year in over 120 low- and middle-income countries starting in 2027. This initiative, announced by Unitaid and the Gates Foundation, aims to provide affordable access to a medication that has demonstrated over 99.9% effectiveness in preventing HIV transmission. Currently, lenacapavir, marketed as Yeztugo by Gilead Sciences, costs approximately $28,000 annually in the United States.
Collaborative Efforts for Accessibility
The price reduction is made possible through partnerships with Indian pharmaceutical companies, including Dr. Reddy's Laboratories and Hetero Labs. These collaborations are designed to manufacture generic versions of lenacapavir, ensuring that the drug is accessible to millions who are at risk of HIV. Carmen Perez Casas, Unitaid's strategic lead for HIV, emphasized the critical nature of this development, stating, "Now, with this product, we can end HIV." The Gates Foundation's Trevor Mundel echoed this sentiment, highlighting the importance of making scientific advances available to those who need them most.
Impact on Global HIV Rates
Despite global efforts that have reduced new HIV infections by 40% since 2010, the UNAIDS reported that 1.3 million people contracted HIV in 2024. The introduction of lenacapavir is expected to significantly impact these statistics, particularly in high-burden countries. Public health experts believe that scaling access to lenacapavir could prevent up to 20% of new infections if made available to just 4% of the population in these regions.
Criticism of Funding Cuts
Amid these advancements, concerns have been raised regarding funding cuts to HIV programs, particularly those linked to the United States' foreign aid policies under the Trump administration. Prince Harry, alongside Charlize Theron and Earvin “Magic” Johnson, has warned that these cuts could lead to an increase in HIV infections and AIDS-related deaths. He stated, "Without urgent action to reverse these crippling funding cuts, six million more people will become infected with HIV while four million will die from AIDS-related causes within the next four years." Critics argue that the reductions in funding jeopardize the progress made in combating HIV/AIDS globally.
Official Statements and Responses
The Gates Foundation has committed over $80 million to accelerate the market readiness of lenacapavir, emphasizing the need for sustained investment in HIV prevention. The foundation's efforts are complemented by agreements with the Global Fund and PEPFAR, which aim to ensure that the new drug reaches those who need it most.
What's Next
As regulatory approvals are anticipated, the rollout of lenacapavir is expected to begin by the end of 2025, with initial supplies reaching at least one African country. This initiative represents a pivotal step toward ending the HIV epidemic, provided that funding and support for HIV programs are maintained.
Verbatim Quotes
- “Now, with this product, we can end HIV.” — Carmen Perez Casas, Unitaid
- “Scientific advances like lenacapavir can help us end the HIV epidemic—if they are made accessible to people who can benefit from them the most,” — Trevor Mundel, Gates Foundation
- “Without urgent action to reverse these crippling funding cuts, six million more people will become infected with HIV while four million will die from AIDS-related causes within the next four years.” — Prince Harry
